← Back to patent-cliff list
ICP-490
Tier C — Watch / tradeICP-490
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：IKZF1, IKZF3
Indications (approved)：Non-Hodgkin lymphoma, Multiple myeloma, 自身免疫疾病
Regional status
US
-
EU
-
China
Phase II
2023-03-29
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ICP-490?
Approved indications include: Non-Hodgkin lymphoma, Multiple myeloma, 自身免疫疾病.
When does the ICP-490 patent expire?
No public expiry year is available for ICP-490 yet; this page updates once verified.
How do I get a quote for ICP-490 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21